Molecular docking and QSAR studies on bioactive compounds isolated from marine organisms into the MUC1 oncoprotein

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 3, Issue SUPPL. 2, 2011, Pages 168-172

  Rajamanikandan, Sundaraj ^a   Sindhu, Thangaraj ^a   Durgapriya, Dhanapal ^a   Anitha, Jebamalai Raj ^a   Akila, Selvaraj ^a   Gopalakrishnan, Velliyur Kanniyapan ^a  

^a KARPAGAM UNIVERSITY   (India)

Author keywords

Anticancer; Bioactive compounds; Docking; Mucins

Indexed keywords

14 HYDROXYTEREZINE D; 18 OXOTRYPROSTATIN; 6 METHOXYSPIROTRYPROSTATIN; ANTIOXIDANT; ASCOCHYTATIN; ASPERGIOLIDE; CARBONARONES A; CARBONARONES B; CYCLIC TERTRAPEPTIDE; DRIMANE SESQUITERPENOIDS A; DRIMANE SESQUITERPENOIDS B; DRIMANE SESQUITERPENOIDS C; MARINOPYRROLES A; MARINOPYRROLES B; MUCIN 1; NATURAL PRODUCT; SCAVENGER; SPICELLAMIDE A; SPICELLAMIDE B; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CHEMOPROPHYLAXIS; DRUG ISOLATION; FUNGUS; MARINE BACTERIUM; MOLECULAR DOCKING; NONHUMAN; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCORING SYSTEM;

EID: 80054773404     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Raina D, Ahmed R, Joshi MD, Yin Z, Wu Z, Kawano T et al. Direct targeting of the MUC1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res 2009; 69: 5133-5141.
2. Agata N, Ahmad R, Kawano T, Raina D, Kharband S, Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 2009; 68: 6136-6144.
3. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell 2007; 27: 992-1004.
4. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D. MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006; 4: 873-883.
5. Macdermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L et al. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010; 3: 1-12.
6. Pitroda SP, Khodarev NN, Beckett MA, Kufe DW, Weicheselbaum RR. MUC1-induced alterations in lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci 2009; 106: 5837-5841.
7. Mikami Y, Hisatsune A, Tashiro T, Isohama Y, Katsuki H. Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. Biochem Biophys Res Commun 2009; 379: 1060-1065.
8. Abrosimov AY, Shkurko OA, Saenko VA, Meirmanov S, Rogounovitch TI, Lushnikov EF et al. Immuno expression of MUC1 in papillary thyroid carcinoma: An association with aberrant expression of B-catenin and cyclin D1 overexpression. International congress series 2007; 1299: 263-270.
9. Cipres A, O'Malley DP, Li K, Finlay D, Baran PS, Vuori K. Sceptrin, a marine natural compound, inhibits cell motility in a variety of cancer cell lines. ACS Cehm Biol 2010; 5: 195-202.
10. Villarreal-Gomez LJ, Soria-Mercado IE, Guerra-Rivas G and Ayala-Sanchez NE. Antibacterial and anticancer activity of seaweeds and bacteria associated with their surface. Revista de Biologia Marina y Oceanografia 2010; 45: 267-275.
11. Genji T, Fukuzawa S, Tachibana K. Distribution and possible function of the marine alkaloid norzoanthamine, in the zoanthid zoanthus sp. Using MALDI imaging mass spectrometry. Mar Biotechnol 2010; 12: 81-87.
12. Wada Y, Fujioka H, Kita Y. Synthesis of the marine phyrroloiminoquinone alkaloids Discorhabdins. Mar Drugs 2010; 8: 1394-416.
13. Jayakanthan M, Wadhwa G, Madhan Mohan T, Arul L, Balasubramanian P and Sundar D. Computer aided drug design for cancer-causing H-Ras P21 mutant protein. Lett Drug Des Discov 2009; 6: 14-20.
14. Debbab A, Aly AH, Lin WH, Proksch P. Bioactive compounds from marine bacteria and fungi. Microbial Biotech 2010; 3: 544-563.
15. Nair SR, Subhashini R, Thiagarajan B. Comparative docking analysis on natural compounds versus a synthetic drug as a therapeutic for acquired immuno deficiency syndrome. Am Med J 2010; 1: 148-150.
16. Sankar AM, Shanmughavel P. In silico docking analysis for viral protein-hemagglutinin-neuraminidase against the synthetic drugs for human parainfluenza virus 3. IJPBS 2010; 2:1-12.
17. Eggink LL, Hoober JK. Peptide mimetics of terminal sugars of complex glycans. Glycobiology Insights 2010; 2: 63-74.
18. Subramanian K, Ramaian AS. Development of a less toxic dichloroacetate analogue by docking and descriptor analysis. Bioinformation 2010; 5:73-76.
19. Croce CM. Oncogens and cancer. N Engl J Med 2008; 358: 502-11.
20. Meshram RJ and Jangle SN. Molecular docking and binding energy studies on nuraminidase of H1N1 reveal possible answer to its resistance for oseltamivir. IJDD 2009; 1: 34-9.
21. Laurie ATR, Jackson RM. Methods for the prediction of proteinligand binding sites for structure-based drug design and virtual ligand screening. Curr Protein Pept Sci 2006; 7: 395-406.
22. Sakkiah S, Thangapandian S, John S, Kwon YJ, Lee KW. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 2010; 45: 2132-40.
23. Mishra NK, Agarwal S, Raghava PS. Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule. BMC Pharmacol 2010; 10: 1-9.
24. Karthikeyan V, Moorthy NSHN and Trivedi P. QSAR study of substituted 2-pyridinyl guanidines as selective urokinase-type plasminogen activator (uPA) inhibitors. J Enzym Inhib Med Chem 2009; 24:6-13.
25. Turabekova MA, Rasulev BF. A QSAR toxicity study of a series of alkaloids with the lycocotonine skeleton. Molecules 2004; 9:194-207.
26. Moy B, Goss PE. Lapatinib: Current status and future directions in breast cancer. The Oncologist 2006; 11:1047-57.